CA2943574A1 - Solid composition comprising amorphous sofosbuvir - Google Patents
Solid composition comprising amorphous sofosbuvir Download PDFInfo
- Publication number
- CA2943574A1 CA2943574A1 CA2943574A CA2943574A CA2943574A1 CA 2943574 A1 CA2943574 A1 CA 2943574A1 CA 2943574 A CA2943574 A CA 2943574A CA 2943574 A CA2943574 A CA 2943574A CA 2943574 A1 CA2943574 A1 CA 2943574A1
- Authority
- CA
- Canada
- Prior art keywords
- weight
- sofosbuvir
- solid composition
- solid
- matrix compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/222—Amides of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14163434 | 2014-04-03 | ||
| EP14163434.5 | 2014-04-03 | ||
| PCT/EP2015/057411 WO2015150561A2 (en) | 2014-04-03 | 2015-04-02 | Solid composition comprising amorphous sofosbuvir |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2943574A1 true CA2943574A1 (en) | 2015-10-08 |
Family
ID=50397065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2943574A Abandoned CA2943574A1 (en) | 2014-04-03 | 2015-04-02 | Solid composition comprising amorphous sofosbuvir |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10493089B2 (enExample) |
| EP (1) | EP3125868A2 (enExample) |
| JP (1) | JP2017512811A (enExample) |
| KR (1) | KR20160142342A (enExample) |
| CN (1) | CN106163529A (enExample) |
| AU (1) | AU2015239018A1 (enExample) |
| CA (1) | CA2943574A1 (enExample) |
| MX (2) | MX2016012934A (enExample) |
| RU (1) | RU2016142819A (enExample) |
| WO (1) | WO2015150561A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111040010A (zh) * | 2019-12-23 | 2020-04-21 | 上海红蓝医药科技有限公司 | 一种索非布韦中间体的合成方法 |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3154526T1 (sl) | 2014-06-13 | 2019-08-30 | Ratiopharm Gmbh | Trdne oblike sofosbuvira |
| WO2016038542A2 (en) * | 2014-09-10 | 2016-03-17 | Mylan Laboratories Limited | Polymorphic forms of sofosbuvir |
| CZ2015443A3 (cs) * | 2015-06-26 | 2017-01-04 | Zentiva, K.S. | Farmaceutická formulace sofosbuviru |
| CA2999215A1 (en) * | 2015-10-07 | 2017-04-13 | Sandoz Ag | Solid pharmaceutical composition comprising amorphous sofosbuvir |
| CZ2016257A3 (cs) * | 2016-05-05 | 2017-11-15 | Zentiva, K.S. | Amorfní forma sofosbuviru, způsob její přípravy a její stabilizace |
| CN106083963A (zh) * | 2016-06-08 | 2016-11-09 | 上海现代制药海门有限公司 | 一种索非布韦晶型6的制备方法 |
| WO2018029262A1 (en) * | 2016-08-12 | 2018-02-15 | Sandoz Ag | Solid pharmaceutical composition comprising amorphous sofosbuvir |
| CZ2016553A3 (cs) | 2016-09-09 | 2018-03-21 | Zentiva, K.S. | Pevná farmaceutická dávková forma obsahující sofosbuvir |
| WO2018078536A1 (en) | 2016-10-26 | 2018-05-03 | Lupin Limited | Stable solid dispersion of sofosbuvir and process for preparation thereof |
| CN108210509A (zh) * | 2016-12-13 | 2018-06-29 | 南京圣和药业股份有限公司 | 新的核苷氨基磷酸脂化合物的组合物及其制备方法 |
| RU2659693C1 (ru) * | 2017-06-30 | 2018-07-03 | Общество с ограниченной ответственностью "Изварино Фарма" | Фармацевтическая композиция, обладающая активностью против ВИЧ-инфекции |
| WO2019134971A1 (en) * | 2018-01-04 | 2019-07-11 | Sandoz Ag | Encapsulated particles comprising a pharmaceutically active ingredient |
| US12116285B2 (en) | 2018-10-05 | 2024-10-15 | Fuji Chemical Industries Co., Ltd. | Porous silica particle composition |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0201450A3 (en) * | 1999-12-08 | 2003-02-28 | Pharmacia Corp Chicago | Solid-state form of celecoxib having enhanced bioavailability, pharmaceutical compositions containing it and their preparation |
| CN1200262C (zh) | 2003-01-10 | 2005-05-04 | 清华大学 | 测量粉末吸附气体量的方法和设备 |
| WO2010017965A2 (en) | 2008-08-11 | 2010-02-18 | Merck Serono S.A. | SOLID LIPID MICROCAPSULES CONTAINING hGH |
| TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| SG184324A1 (en) | 2010-03-31 | 2012-11-29 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| WO2013101550A1 (en) | 2011-12-29 | 2013-07-04 | Abbvie Inc. | Solid compositions comprising an hcv inhibitor |
| AU2012362858A1 (en) * | 2011-12-30 | 2014-07-24 | Chevron U.S.A. Inc. | Process, method, and system for removing heavy metals from fluids |
| PT3038601T (pt) * | 2013-08-27 | 2020-06-30 | Gilead Pharmasset Llc | Formulação combinada de dois compostos antivirais |
-
2015
- 2015-04-02 KR KR1020167030432A patent/KR20160142342A/ko not_active Withdrawn
- 2015-04-02 MX MX2016012934A patent/MX2016012934A/es unknown
- 2015-04-02 JP JP2016560461A patent/JP2017512811A/ja not_active Ceased
- 2015-04-02 CN CN201580018422.4A patent/CN106163529A/zh not_active Withdrawn
- 2015-04-02 RU RU2016142819A patent/RU2016142819A/ru not_active Application Discontinuation
- 2015-04-02 CA CA2943574A patent/CA2943574A1/en not_active Abandoned
- 2015-04-02 US US15/129,149 patent/US10493089B2/en not_active Expired - Fee Related
- 2015-04-02 EP EP15713526.0A patent/EP3125868A2/en not_active Withdrawn
- 2015-04-02 AU AU2015239018A patent/AU2015239018A1/en not_active Abandoned
- 2015-04-02 WO PCT/EP2015/057411 patent/WO2015150561A2/en not_active Ceased
-
2016
- 2016-09-30 MX MX2019009842A patent/MX2019009842A/es unknown
-
2019
- 2019-08-23 US US16/550,057 patent/US20190381085A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111040010A (zh) * | 2019-12-23 | 2020-04-21 | 上海红蓝医药科技有限公司 | 一种索非布韦中间体的合成方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20170100422A1 (en) | 2017-04-13 |
| RU2016142819A (ru) | 2018-05-10 |
| MX2019009842A (es) | 2019-10-22 |
| WO2015150561A3 (en) | 2016-01-28 |
| RU2016142819A3 (enExample) | 2018-05-10 |
| EP3125868A2 (en) | 2017-02-08 |
| AU2015239018A1 (en) | 2016-10-13 |
| KR20160142342A (ko) | 2016-12-12 |
| US10493089B2 (en) | 2019-12-03 |
| US20190381085A1 (en) | 2019-12-19 |
| CN106163529A (zh) | 2016-11-23 |
| WO2015150561A2 (en) | 2015-10-08 |
| JP2017512811A (ja) | 2017-05-25 |
| MX2016012934A (es) | 2016-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2943574A1 (en) | Solid composition comprising amorphous sofosbuvir | |
| WO2017121806A1 (en) | Pharmaceutical composition of selexipag | |
| NZ516760A (en) | Non-crystalline cefuroxime axetil solid dispersant, process for preparing same and composition for oral administration thereof | |
| WO2017060374A1 (en) | Solid pharmaceutical composition comprising amorphous sofosbuvir | |
| KR102333463B1 (ko) | 리바록사반을 포함하는 경구 투여용 약학 조성물 및 이의 제조방법 | |
| WO2012060788A1 (en) | Formulations of cephalosporins with controlled moisture content | |
| CA2975813A1 (en) | Pharmaceutical compositions comprising ledipasvir and sofosbuvir | |
| WO2017211779A1 (en) | Pharmaceutical compositions of betrixaban maleate | |
| KR101446129B1 (ko) | 프란루카스트-함유 고형 제제의 제조방법 | |
| CA3033319A1 (en) | Solid pharmaceutical composition comprising amorphous sofosbuvir | |
| JP2013544272A5 (enExample) | ||
| AU2007300071A1 (en) | Atorvastatin pharmaceutical compositions | |
| WO2012060790A2 (en) | Water dispersible cefpodoxime proxetil formulations | |
| WO2012026907A2 (en) | Cefpodoxime proxetil formulations | |
| EP2803353B1 (en) | Compositions of Imatinib | |
| WO2013151516A1 (en) | Film tablet formulations comprising cefuroxime axetil and clavulanic acid | |
| WO2012060787A1 (en) | Oral dosage forms comprising cefdinir and carboxymethyl cellulose calcium | |
| WO2019030387A1 (en) | SOLID COMPOSITION COMPRISING AMORPHOUS SOFOSBUVIR AND AMORPHOUS DACLATASVIR | |
| JP2013103924A (ja) | 結晶性アトルバスタチンカルシウム含有錠剤の製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20211123 |